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Summary
Background Few trials of adjuvant breast radiotherapy have incorporated patient-reported breast symptoms and 
related areas of quality of life. We assessed these measures in a quality-of-life study that was part of the randomised 
START (Standardisation of Breast Radiotherapy) trials. 
Methods In START trial A, 2236 patients were randomly assigned to receive either 39 Gy or 41·6 Gy delivered in 
13 fractions over 5 weeks or a global standard of 50 Gy in 25 fractions. In START trial B, 2215 women were randomly 
assigned to receive either 40 Gy in 15 fractions over 3 weeks or the same control regimen (50 Gy in 25 fractions) as in 
trial A. 2739 patients were eligible for the quality-of-life study of whom 2208 (81%) were accrued (1129 patients from 
trial A and 1079 from trial B). Participants completed the EORTC QLQ-C30 and BR23 questionnaires and protocol-
speciﬁ c radiotherapy items up to 5 years after radiotherapy. We compared results across regimens with generalised 
estimating equations and survival analyses. The START trials are registered, ISRCTN59368779.
Findings At 5 years, up to 40% women reported moderate or marked changes to the breast after radiotherapy, and arm 
and shoulder pain aﬀ ected up to a third of patients. Breast symptoms and body image concerns reduced over time. 
Rates of radiotherapy adverse eﬀ ects were lower for the 39 Gy regimen in trial A and the 40 Gy regimen in trial B, 
compared with the 50 Gy control regimen; rates of radiotherapy adverse eﬀ ects were similar between the 41·6 Gy and 
50 Gy regimens in trial A. Adverse change in skin appearance was signiﬁ cantly lower for patients who received 39 Gy 
compared with those who received 50 Gy (HR 0·63, 95% CI 0·47–0·84) and for those who received 40 Gy compared 
with those who received 50 Gy (0·76, 0·60–0·97); no signiﬁ cant diﬀ erence was observed between patients who 
received 41·6 Gy and those who received 50 Gy in trial A (0·83, 0·63–1·08). Patient self-ratings of breast symptoms 
discriminated a 10% diﬀ erence in randomised dose intensity. Up to a third of women reported moderate or marked 
pain in the arm and shoulder over 5 years whilst more than 10% experienced moderate or marked arm and hand 
swelling, with no signiﬁ cant diﬀ erence in arm/shoulder subscale scores between the regimens in trial A or trial B; 
many baseline arm and shoulder symptoms were associated with prior surgery.  
Interpretation A substantial proportion of women report moderate or marked breast, arm, and shoulder symptoms over 
5 years of follow-up after radiotherapy, but with no detriment to body image. Nonetheless, most patients stand to gain 
from hypofractionated radiotherapy regimens with a potential for fewer adverse eﬀ ects; this strengthens the evidence 
from the START trials for hypofractionated regimens for women requiring radiotherapy for early breast cancer.
Funding Cancer Research UK, UK Medical Research Council, UK Department of Health.
Introduction
The safety and eﬀ ectiveness of radiotherapy schedules that 
deliver a lower total dose in fewer, larger fractions than the 
international standard regimen has long been uncertain, 
despite widespread use in early breast cancer. In the UK, 
two randomised trials (Standardisation of Breast 
Radiotherapy [START] trials A and B) were run concurrently 
to compare the international standard dose (50 Gy delivered 
in 25 fractions over 5 weeks) with alternative schedules 
based on fewer larger fractions. In trial A,1 doses of 39 Gy 
and 41·6 Gy given in 13 fractions over 5 weeks were 
compared with the standard international regimen. Trial 
B2 was a pragmatic non-inferiority trial comparing the 
same standard dose with 40 Gy in 15 fractions over 3 weeks, 
a commonly used regimen in the UK. The results of trial A 
showed that rates of late-occurring adverse eﬀ ects assessed 
from photographs were signiﬁ cantly lower for the 39 Gy 
regimen compared with the 50 Gy control. The 41·6 Gy 
regimen was similar to 50 Gy in terms of radiotherapy 
adverse eﬀ ects and local tumour control.1 In trial B, for the 
40 Gy regimen, local tumour control was at least as good as 
with 50 Gy, and late adverse eﬀ ects were reduced.2
Regimens with shorter schedules could have a positive 
eﬀ ect on radiotherapy resource use and patients’ 
convenience. However, over the years, concerns about 
lengthy treatments might have contributed to women’s 
choice of mastectomy alone over breast-conserving surgery 
plus radiotherapy,3 while age and geographic location have 
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also been cited as predictors of mastectomy.4 This situation 
is not desirable, since good-to-excellent breast cosmesis 
for most patients has been reported after breast-conserving 
surgery and a range of radiotherapy schedules,5–8 albeit 
with variable levels of functional morbidity.9,10 
In a pilot study to the START trials, photographic assess-
ments showed that a third of women had some change in 
breast appearance over 10 years of follow-up, with evidence 
of variation according to fractionation regimen over time.11 
Rates of marked radiation eﬀ ects assessed from 
photographs were signiﬁ cantly higher for patients allocated 
a 42·9 Gy regimen delivered in 13 fractions compared with 
50 Gy in 25 fractions, with lowest rates for 39 Gy in 
13 fractions (although not statistically signiﬁ cant). However, 
patient’s ratings of the eﬀ ect of radiotherapy on cosmesis 
and breast, arm, and shoulder symptoms were not recorded 
in the pilot study and are generally poorly documented in 
published work.3,12 
The START trials built on the experience of the pilot 
study by making a minor adjustment to one of the 
radiotherapy doses for use in trial A and by including a 
detailed quality-of-life study in trials A and B.1,2 Here, 
using data from each trial separately, we compare 
radiotherapy schedules with respect to patients’ self-
assessments of normal tissue eﬀ ects on the basis of 
changes in breast, arm, shoulder symptoms and function, 
and body image over 5 years of follow-up.
Methods
Patients 
Participation in the START trials quality-of-life study was 
open to all radiotherapy centres recruiting patients to the 
START trials, for which full details of patients and 
procedures have been published.1,2 Women with early-
stage invasive breast cancer needing radiotherapy after 
primary surgery were eligible for the START trials if they 
were older than 18 years, did not have breast reconstruction 
before radiotherapy, and were available for follow-up. All 
centres could choose at the outset whether or not to 
participate in the quality-of-life study, with the expectation 
that all patients in participant centres would be 
approached for the quality-of-life study. No diﬀ erences 
were recorded in terms of radiotherapy planning and 
delivery between centres opting in and out of the quality-
of-life study (data not shown). The START trials included 
a rigorous radiotherapy quality-assurance programme, 
which ensured that the START protocol was adhered to 
at all centres. 
We reached accrual targets for the quality-of-life study 
much earlier than expected, so we decided to continue 
beyond the target sample size to boost precision of 
estimates and to make the most of the opportunity to 
accumulate a unique dataset. Trial B completed accrual 
ahead of trial A. In the last year of recruitment we focused 
accrual in the quality-of-life study on speciﬁ c subgroups—
those who had undergone mastectomy, had received 
chemotherapy or were intended to have lymph-node 
irradiation in trial A, and those who were intended to 
have lymph-node irradiation in trial B. 
The South Thames Multi-Research Ethics Committee 
approved the START trials in September, 1998, and the 
local ethics committees of all participating centres also 
gave approval. We obtained written informed consent for 
all patients. The Cancer Research UK’s Clinical Trials 
and Statistics Unit at the Institute of Cancer Research 
(ICR-CTSU), Sutton, UK, coordinated the START Trials. 
Full details of the organisational aspects of the trials have 
been published previously.1,2
Procedures
Women in START trial A were randomly assigned to 
radiotherapy over a 5-week period at either 50 Gy in 
25 fractions of 2·0 Gy (control) or 41·6 Gy in 13 fractions 
of 3·2 Gy or 39 Gy in 13 fractions of 3·0 Gy.1 Treatment 
entailed ﬁ ve fractions per week in the control group and 
ﬁ ve treatments every 2 weeks in each of the 13 fraction 
schedules (three fractions one week and two the next). In 
trial B, patients were randomly allocated radiotherapy at 
either 50 Gy in 25 fractions of 2·0 Gy over 5 weeks 
(control) or 40 Gy in 15 fractions of 2·67 Gy over 3 weeks 
(ie, ﬁ ve fractions per week for both schedules).2 
Randomisation was done via telephone at ICR-CTSU. 
Treatment allocation could not be masked because of the 
diﬀ erent daily schedules of the radiotherapy regimens. 
Computer-generated random permuted blocks were used 
as the method of allocation, with patients stratiﬁ ed by 
hospital, type of surgery (breast-conserving surgery or 
mastectomy), and intention to give a tumour-bed boost 
or not. At least 2 weeks was needed between exposure to 
chemotherapy and radiotherapy, and a radiotherapy boost 
to the tumour bed was prescribed according to local 
policy. Full details of the radiotherapy planning and 
treatment are presented elsewhere.1,2 
Patients who consented to participate in the quality-of-
life study completed a questionnaire booklet in the breast 
clinic before randomisation. We mailed subsequent 
questionnaires for completion at home at 6, 12, 24, and 
60 months post-randomisation (after checking the indi-
vidual’s current health status with their hospital team or 
family doctor). We prompted patients by telephone or letter 
if questionnaires were not returned within 3 weeks. Full 
details of the quality-of-life study are available elsewhere.13 
We assessed quality of life with the EORTC (European 
Organisation for Research and Treatment of Cancer) 
general cancer scale QLQ-C3014 and breast-cancer module 
(BR23).15 Both measures use a four-point response format 
for individual items (not at all, a little, quite a bit, very 
much). BR23 consists of six subscales, of which three 
were used in the analysis: breast symptoms subscale 
(four items [pain, swelling, oversensitivity, and skin 
problems in the breast]), arm subscale (three items 
[swelling in arm or hand, arm or shoulder pain, and 
diﬃ  culty moving the arm]), and body image (four items). 
Other functioning and symptom subscales and items of 
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Figure 1: Trial proﬁ les of patients from START trial A (A) and trial B (B) quality-of-life study
1344 patients eligible for QoL study
1129 patients entered into QoL study
379 randomly allocated 50 Gy 
in 25 fractions over 5 weeks
7 with no baseline QoL data
 2 withdrew
  (1 due to depression)
 1 recurrence found
 4 not known
13 with baseline but no follow-up 
QoL data
 7 withdrew 
 3 died
 1 moved
 2 not known
2 with no baseline QoL data 
(not known)
10 with baseline but no follow-up 
QoL data
 2 withdrew
 2 died
 2 moved
 4 not known
8 with no baseline QoL data 
 3 withdrew
 1 with metastases
 4 not known
9 with baseline but no follow-up 
QoL data
 2 withdrew
 1 died
 6 not known
376 randomly allocated 41·6 Gy 
in 13 fractions over 5 weeks
374 randomly allocated 39 Gy 
in 13 fractions over 5 weeks
359 with baseline QoL data
and at least one follow-up
364 with baseline QoL data
and at least one follow-up
357  with baseline QoL data
and at least one follow-up
215 not entered into QoL study
 • Accrual rates lower when centres ﬁrst began accrual
 • Resource limitations at centres
 • Centres not in photographic study opted to only enter mastectomy 
  patients (because not eligible for photos) into QoL study
 • Patient’s refusal
1395 patients eligible for QoL study
1079 patients entered into QoL study
535 randomly allocated 50 Gy 
in 25 fractions over 5 weeks
5 with no baseline QoL data
 1 withdrew
 2 booklet completed but lost
 1 not entered into study as accrual had closed
 1 not known
19 with baseline but no follow-up QoL data
 7 withdrew 
 5 died
 1 had psychological problems
 1 trial deviation (opted for mastectomy 
  instead of radiotherapy)
 1 booklet completed but lost
 4 not known
5 with no baseline QoL data 
 1 booklet completed but lost
 1 ineligible (patient had concurrent chemotherapy)
 3 not known
13 with baseline but no follow-up QoL data
 4 withdrew
 3 died
 1 moved
 1 lost to follow-up
 4 not known
544 randomly allocated 40 Gy 
in 15 fractions over 3 weeks
511 with baseline QoL data
and at least one follow-up
526 with baseline QoL data
and at least one follow-up
316 not entered into QoL study
 • Accrual rates lower when centres ﬁrst began accrual
 • Resource limitations at centres
 • Centres not in photographic study opted to only enter mastectomy 
  patients (because not eligible for photos) into QoL study
 • Patient’s refusal
B
A
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the BR23 and QLQ-C30 are outside the aim of this 
analysis and are not presented here.
We constructed protocol-speciﬁ c items to assess 
particular post-radiotherapy eﬀ ects on normal tissues (not 
covered in the EORTC quality-of-life scales), with the same 
four-point response format as the EORTC measures. 
These items included change in skin appearance in the 
area of the aﬀ ected breast (to account for telangiectasia 
and other eﬀ ects), overall change in breast appearance (to 
account for asymmetry and distortion), ﬁ rmness to touch 
of the aﬀ ected breast (to account for ﬁ brosis), and 
reduction in size of the aﬀ ected breast (to account for 
shrinkage); the last three items only applied to patients 
who had completed breast-conserving surgery. Cronbach’s 
alpha coeﬃ  cient for these four post-radiotherapy items 
was 0·72, indicating satisfactory internal consistency. An 
additional item assessed shoulder stiﬀ ness. 
We assessed body image with a validated, cancer-speciﬁ c, 
ten-item scale (body image scale),16 which includes the 
BR23 body image subscale. Again, the same four-point 
response format as the EORTC measures was used. 
Items included change in self-consciousness with 
appearance, feeling less physically attractive, less sexually 
attractive, less feminine, dissatisfaction with appearance 
when dressed, dissatisfaction with body or scars, body 
feeling less whole, diﬃ  culty looking at self naked, and 
avoidance of people because of appearance. We included 
the ten-item body image scale in this analysis. 
Statistical analysis
We estimated that a minimum of 200 patients per 
radiotherapy schedule would be needed to compare 
quality-of-life endpoints. This number would allow 
estimation of the proportion of patients with a particular 
side-eﬀ ect or speciﬁ ed degree of morbidity on a quality-
of-life domain with a precision of at least 7% (maximum 
SE 3·5%), and it would enable detection of diﬀ erences 
between every test regimen and the control schedule of at 
least 20% (with 90% power and α=0·01, allowing for 
testing of multiple endpoints). We included an allowance 
of 10% to account for non-completion of questionnaires 
due to illness, death, or non-compliance. 
For analyses, a baseline and at least one follow-up 
assessment were needed. We categorised questionnaire 
item scores for BR23 and protocol items according to 
whether or not a patient had ever recorded an item as 
“quite a bit” or “very much”, corresponding to moderate 
or marked eﬀ ects. We then used survival analysis to 
measure time to ﬁ rst reporting of a moderate or marked 
event, using the date of completion of the questionnaire 
to calculate length of follow-up from randomisation. We 
calculated Kaplan-Meier estimates of 5-year rates, along 
with hazard ratios obtained from Cox’s proportional-
hazards regression analysis (with 95% CI). For symptoms 
that were included in the baseline questionnaire, the 
Cox’s proportional-hazards regression model included a 
term for the baseline score. We tested radiation dose 
Trial A (n=1129) Trial B (n=1079)
Age (years)* 57·0 (10·8) 56·7 (10·0)
Type of surgery
Breast-conserving surgery 885 (78%) 946 (88%)
Mastectomy 244 (22%) 133 (12%)
Time since surgery (weeks)† 9·3 (5·7–21·6) 8·1 (5·3–17·6)
Adjuvant systemic therapy
None 93 (8%) 35 (3%)
Chemotherapy only 109 (10%) 115 (11%)
Tamoxifen only 577 (51%) 689 (64%)
Chemotherapy and tamoxifen 318 (28%) 219 (20%)
Other 25 (2%) 17 (2%)
Unknown 7 (1%) 4 (<1%)
Pathological node status 
Positive 379 (34%) 313 (29%)
Negative 723 (64%) 728 (67%)
Unknown 27 (2%) 38 (4%)
Boost (breast-conserving surgery patients only)
Yes 628 (71%) 481 (51%)
No 250 (28%) 455 (48%)
Unknown 7 (1%) 10 (1%)
Pathological tumour size (cm)† 2 (1·4–2·7) 1·7 (1·2–2·3)
Tumour size distribution
<1 41 (4%) 141 (13%)
1 to <2 507 (45%) 500 (46%)
2 to <3 312 (28%) 306 (28%)
≥3 263 (23%) 127 (12%)
Unknown 6 (<1%) 5 (<1%)
Tumour grade 
1 230 (20%) 286 (27%)
2 546 (48%) 484 (45%)
3 329 (29%) 283 (26%)
Unknown 24 (2%) 26 (2%)
Lymphatic radiotherapy 
Yes 262 (23%) 103 (10%)
No 861 (76%) 965 (89%)
Unknown 6 (1%) 11 (1%)
Axillary surgery 
Yes 1102 (98%) 1042 (97%)
No 27 (2%) 37 (3%)
Breast size (from photographs)
Small 91 (8%) 79 (7%)
Medium 631 (56%) 668 (62%)
Large 119 (11%) 144 (13%)
Unknown 37 (3%) 45 (4%)
Not in photographic study 251 (22%) 143 (13%)
Surgical deﬁ cit (from photographs)
Small 495 (44%) 510 (47%)
Medium 271 (24%) 299 (28%)
Large 75 (7%) 82 (8%)
Unknown 37 (3%) 45 (4%)
Not in photographic study 251 (22%) 143 (13%)
Data are number (%) unless stated otherwise. *Data are mean (SD). †Data are median (IQR).
Table 1: Characteristics of patients included in quality-of-life study
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response by direct comparison of the 41·6 Gy and 39 Gy 
regimens in trial A. 
For continuous symptom scores (breast and arm 
symptoms, body image), we summarised distributions at 
every timepoint according to radiotherapy regimen with 
medians and IQR, since data were skewed and no suitable 
transformation could be found. We compared subscale 
scores for breast and arm symptoms and body image 
scale summary scores over the 5 years of follow-up and 
between radiotherapy regimens with generalised 
estimating equations, which allow for correlation within 
repeated observations per individual.17 
Since patients were stratiﬁ ed at randomisation by type 
of primary surgery and intention to give a radiotherapy 
boost to the tumour bed, we undertook stratiﬁ ed analyses 
and tests for interaction to see whether the relative eﬀ ects 
of the radiotherapy regimens varied according to these 
subgroups. For the continuous subscales of breast and 
arm symptoms and body image, stratiﬁ ed analyses 
included all follow-up data in the generalised estimating 
equation models, but only 5-year data are presented for 
simplicity. We also did a secondary analysis of arm, 
shoulder, and hand symptoms, with adjustment for 
axillary surgery and lymphatic radiotherapy, but since 
this modiﬁ cation made almost no diﬀ erence to the 
treatment eﬀ ects, unadjusted results are presented. 
We undertook all analyses with SPSS version 15.0. 
Analysis was on an intention-to-treat basis, which is 
appropriate for assessment of safety in a trial in which 
compliance with allocated treatment is high (2175 of 2208 
[99%] patients in the quality-of-life study received their 
allocated radiotherapy regimen) because underestimation 
of adverse risks is not a concern. The START trials are 
registered, number ISRCTN59368779.
Role of the funding source
The funding sources provided peer-reviewed approval for 
the trials and were observers on the Trial Steering 
Committee, but had no other role in the study. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between January, 1999, and December, 2002, 4451 
women were enrolled into the START trials (2236 from 
17 centres in trial A and 2215 from 23 centres in trial B). 
Of these, 2208 patients were accrued into the quality-of-
life study, with 1129 from 13 centres in trial A and 1079 
from 21 centres in trial B (ﬁ gure 1). The proportion of 
every centre’s trial patients entered into the quality-of 
life-study varied. Reasons for non-accrual were not 
obtained on an individual basis; at some centres, non-
accrual was due to resource limitations, and at others, 
patients who had completed breast-conserving surgery 
were not recruited into the quality-of-life study if centres 
did not have the facilities to participate in the 
photographic assessment study. Over the whole accrual 
period, the median proportion per centre of trial patients 
entered into the quality-of-life study out of those eligible 
was 91% (IQR 75–97).
Table 1 shows characteristics of patients accrued into 
the quality-of-life study. More women received adjuvant 
chemotherapy (with or without tamoxifen) in trial A 
(38%, 427/1129) than in trial B (31%, 334/1079), consistent 
with diﬀ erences in the composition of patients in the two 
trials (table 1). Most women had grade 1 or 2 tumours 
and were on endocrine therapy at the start of radiotherapy. 
In each regimen in trial A, a radiotherapy boost to the 
tumour bed was given to just under three-quarters of 
women who had completed breast-conserving surgery. 
In each regimen in trial B, about half of breast-conserving 
surgery patients received a boost.
Adherence to randomised treatment in each trial was 
very high (1110/1129 [98%] in trial A and 1065/1079 [99%] 
in trial B).1,2 The proportion of completed quality-of-life 
questionnaires (based on the number of returned vs 
expected forms) was high, with 99% at baseline, decreasing 
only slightly over time to 91% at year 5.. Reasons for non-
return of questionnaires included patient’s withdrawal 
from the quality-of-life study, change of address, recurrence, 
and death, although most patients chose to remain in the 
study after a recurrence (ﬁ gure 1). In terms of number of 
0 months 6 months 12 months 24 months 60 months
BR23 breast symptoms subscale (0–100)
Trial A
50 Gy 16·7 (8·3–25·0) 16·7 (8·3–33·3) 16·7 (8·3–25·0) 8·3 (0–25·0) 8·3 (0–25·0)
41·6 Gy 16·7 (8·3–25·0) 16·7 (8·3–33·3) 16·7 (0–25·0) 8·3 (0–25·0) 8·3 (0–16·7)
39 Gy 16·7 (8·3–25·0) 16·7 (8·3–25·0) 16·7 (0–25·0) 8·3 (0–16·7) 8·3 (0–16·7)
Trial B
50 Gy 16·7 (8·3–25·0) 16·7 (8·3–33·3) 16·7 (8·3–25·0) 8·3 (0–16·7) 8·3 (0–16·7)
40 Gy 16·7 (8·3–25·0) 16·7 (8·3–33·3) 16·7 (0–25·0) 8·3 (0–16·7) 8·3 (0–16·7)
BR23 arm or shoulder symptoms subscale (0–100)
Trial A
50 Gy 22·2 (0–33·3) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 
41·6 Gy 11·1 (0–33·3) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
39 Gy 22·2 (11·1–33·3) 11·1 (0–33·3) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
Trial B
50 Gy 11·1 (11·1–33·3) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
40 Gy 22·2 (11·1–33·3) 11·1 (0–33·3) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
Body image scale (0–30)
Trial A
50 Gy 3·0 (1·0–8·0) 3·0 (0–7·0) 3·0 (0–7·0) 2·0 (0–7·0) 2·0 (0–7·0) 
41·6 Gy 4·0 (1·0–8·7) 2·0 (0–6·0) 2·0 (0–6·0) 2·0 (0–6·0) 2·0 (0–7·0)
39 Gy 4·0 (1·0–9·0) 2·0 (0–7·0) 2·0 (0–7·0) 2·0 (0–7·0) 2·0 (0–6·0)
Trial B
50 Gy 3·0 (0–8·0) 2·0 (0–6·0) 1·0 (0–5·0) 1·0 (0–5·7) 1·5 (0–6·0) 
40 Gy 3·0 (0–7·0) 2·0 (0–6·0) 1·0 (0–5·0) 1·0 (0–5·0) 1·0 (0–5·0)
Data are median (IQR). Higher scores indicate more symptoms or concerns.
Table 2: Breast, arm, or shoulder symptoms and body image scale scores, according to radiotherapy 
regimen, over time from randomisation
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Figure 2: Forest plots of normal tissue eﬀ ects assessed as moderate or marked by patients, according to radiotherapy regimen
Positions of squares in the forest plot show the estimate of the hazard ratio describing relative eﬀ ect of the test schedule compared with control, with the 95% CI 
represented by horizontal lines. Squares to the left of the vertical line indicate when rates of adverse eﬀ ects are lower in the test schedule compared with control; 
estimates to the right of the line indicate whether rates are higher in the test schedule. Size of squares is proportional to the precision of the estimate, with larger 
squares indicating greater precision. *In patients who had completed breast-conserving surgery only. (A) START trial A, 41·6 Gy vs 50 Gy. (B) START trial A, 39 Gy vs 
50 Gy. (C) START Trial B, 40 Gy vs 50 Gy.
0·4 0·6 0·8
Favours 40 Gy Favours 50 Gy
1·0 1·2 1·4 1·6
Favours 39 Gy Favours 50 Gy
Favours 41·6 Gy Favours 50 Gy
   
Breast symptoms
 Change in breast appearance since radiotherapy* 41·0 (35·0–46·9) 41·9 (36·1–47·8) 1·05 (0·82–1·35) 0·6781
 Breast hardness since radiotherapy* 43·2 (37·2–49·2) 45·0 (39·1–50·8) 1·09 (0·85–1·39) 0·5073 
 Breast shrinkage since radiotherapy* 22·6 (17·5–27·7) 24·4 (19·3–29·5) 1·09 (0·80–1·47) 0·5841
 Change in skin appearance since radiotherapy 31·6 (26·6–36·6) 25·3 (20·7–29·8) 0·83 (0·63–1·08) 0·1663
 Skin problems on or in area of aﬀected breast 16·9 (12·8–20·9) 16·6 (12·7–20·6) 1·01 (0·71–1·43) 0·9468
 Pain in area of aﬀected breast 21·4 (17·0–25·8) 23·9 (19·4–28·3) 1·17 (0·86–1·58) 0·3175
 Oversensitivity in area of aﬀected breast 23·3 (18·7–27·8) 22·1 (17·7–26·4) 1·09 (0·81–1·47) 0·5668
 Swelling in area of aﬀected breast 15·5 (11·7–19·4) 12·2 (8·8–15·6) 0·81 (0·55–1·20) 0·2933
Arm or shoulder symptoms 
 Pain in arm or shoulder 30·9 (25·9–35·9) 30·2 (25·3–35·0) 1·00 (0·77–1·29) 0·9967
 Shoulder stiﬀness 19·8 (15·5–24·1) 16·0 (12·2–19·9) 0·89 (0·64–1·23) 0·4726
 Diﬃculty in raising or moving arm sideways 15·0 (11·1–18·9) 14·1 (10·4–17·7) 0·97 (0·67–1·39) 0·8576
 Swelling in arm or hand 14·5 (10·7–18·3) 11·8 (8·3–15·2) 0·84 (0·57–1·23) 0·3742
Breast symptoms
 Change in breast appearance since radiotherapy* 41·0 (35·0–46·9) 34·1 (28·4–39·8) 0·84 (0·65–1·08) 0·1775
 Breast hardness since radiotherapy* 43·2 (37·2–49·2) 35·0 (29·3–40·7) 0·79 (0·61–1·04) 0·0894 
 Breast shrinkage since radiotherapy* 22·6 (17·5–27·7) 22·9 (17·8–28·0) 1·00 (0·73–1·37) 0·9823
 Change in skin appearance since radiotherapy 31·6 (26·6–36·6) 21·7 (17·3–26·1) 0·63 (0·47–0·84) 0·0019
 Skin problems on or in area of aﬀected breast 16·9 (12·8–20·9) 16·5 (12·4–20·5) 0·90 (0·63–1·28) 0·5539
 Pain in area of aﬀected breast 21·4 (17·0–25·8) 20·1 (15·8–24·4) 0·97 (0·70–1·32) 0·8311
 Oversensitivity in area of aﬀected breast 23·3 (18·7–27·8) 19·1 (14·9–23·3) 0·79 (0·58–1·09) 0·1541
 Swelling in area of aﬀected breast 15·5 (11·7–19·4) 12·0 (8·6–15·5) 0·73 (0·49–1·08) 0·1182
Arm or shoulder symptoms 
 Pain in arm or shoulder 30·9 (25·9–35·9) 32·5 (27·5–37·5) 1·07 (0·82–1·38) 0·6252
 Shoulder stiﬀness 19·8 (15·5–24·1) 18·1 (13·9–22·2) 0·84 (0·60–1·17) 0·3015
 Diﬃculty in raising or moving arm sideways 15·0 (11·1–18·9) 13·9 (10·2–17·7) 0·97 (0·68–1·38) 0·8586
 Swelling in arm or hand 14·5 (10·7–18·3) 14·8 (10·9–18·7) 0·90 (0·62–1·32) 0·6030
   
Breast symptoms
 Change in breast appearance since radiotherapy* 41·2 (36·6–45·9) 35·5 (30·9–40·0) 0·84 (0·69–1·03) 0·0956
 Breast hardness since radiotherapy* 42·8 (38·2–47·5) 38·4 (33·8–42·9) 0·88 (0·72–1·08) 0·2142 
 Breast shrinkage since radiotherapy* 26·3 (22·1–30·5) 23·8 (19·8–27·8) 0·86 (0·68–1·09) 0·2176
 Change in skin appearance since radiotherapy 28·3 (24·3–32·3) 23·0 (19·4–26·7) 0·76 (0·60–0·97) 0·0262
 Skin problems on or in area of aﬀected breast 18·7 (15·3–22·1) 17·0 (13·7–20·2) 0·88 (0·67–1·17) 0·3820
 Pain in area of aﬀected breast 22·7 (19·0–26·4) 20·7 (17·2–24·2) 0·94 (0·73–1·22) 0·6532
 Oversensitivity in area of aﬀected breast 23·0 (19·3–26·8) 23·7 (20·0–27·4) 1·11 (0·86–1·42) 0·4193
 Swelling in area of aﬀected breast 12·4 (9·5–15·3) 10·6 (7·9–13·2) 0·91 (0·64–1·30) 0·6112
Arm or shoulder symptoms 
 Pain in arm or shoulder 32·0 (27·9–36·2) 32·0 (27·9–36·1) 1·02 (0·82–1·25) 0·8746
 Shoulder stiﬀness 19·3 (15·8–22·8) 18·3 (14·9–21·7) 0·95 (0·73–1·25) 0·7308
 Diﬃculty in raising or moving arm sideways 17·0 (13·6–20·3) 15·9 (12·7–19·1) 0·97 (0·72–1·29) 0·8154
 Swelling in arm or hand 12·9 (9·9–15·9) 12·2 (9·2–15·1) 1·05 (0·75–1·48) 0·7658
Hazard ratio (95% CI) pKaplan-Meier 5-year event rate (%; 95% CI)
50 Gy 41·6 Gy
50 Gy 39 Gy
50 GyC
B
A START trial A, 41·6 Gy vs 50 Gy
START trial A, 39 Gy vs 50 Gy
START trial B, 40 Gy vs 50 Gy 40 Gy
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assessments completed per patient (including at baseline), 
approximately three-quarters of women returned all ﬁ ve 
booklets and the remaining quarter returned at least two. 
The number of women with a baseline and at least one 
follow-up assessment (denominators for the analysis) were 
1080 in trial A and 1037 in trial B, representing 96% of the 
2208 patients accrued into the quality-of-life study 
(ﬁ gure 1). 
With respect to breast, arm, and shoulder symptoms, 
the most frequently reported adverse eﬀ ects in women 
who had completed breast-conserving surgery were 
breast hardness and overall change in breast appearance 
after radiotherapy (estimated 5-year rates 41% and 39%, 
respectively, with moderate or marked symptoms in both 
trials). In all radiotherapy regimens, the BR23 breast 
symptom subscale score declined signiﬁ cantly from 
baseline to 60 months (p<0·0001), but no signiﬁ cant 
diﬀ erences between regimens were noted in trial A 
(p=0·5558) or trial B (p=0·8757; table 2). The rate of 
moderate or marked change in skin appearance after 
radiotherapy in all women (breast-conserving surgery 
and mastectomy) was signiﬁ cantly lower for the 39 Gy 
versus 50 Gy regimen in trial A (hazard ratio 0·63, 
95% CI 0·47–0·84) and for the 40 Gy versus 50 Gy 
regimen in trial B (0·76, 0·60–0·97), whereas the 
41·6 Gy and 50 Gy regimens in trial A did not diﬀ er 
signiﬁ cantly (0·83, 0·63–1·08; ﬁ gure 2). Although no 
further signiﬁ cant diﬀ erences were found, there was a 
similar pattern for other post-radiotherapy eﬀ ects in the 
breast, with lowest rates of adverse changes in the 39 Gy 
regimen of trial A and the 40 Gy regimen in trial B, and 
similar rates in the 41·6 Gy regimen compared with 50 
Gy (ﬁ gure 2). Diﬀ erences between regimens usually 
arose by 1 year after randomisation and then persisted. 
Direct comparison of the 41·6 Gy and 39 Gy regimens in 
trial A provided some evidence of a radiation dose 
response. Lower rates for some endpoints were noted in 
the 39 Gy schedule (eg, breast hardness since radiotherapy, 
hazard ratio 0·73, 95% CI 0·56–0·95; oversensitivity in 
area of aﬀ ected breast 0·72, 0·52–0·98; change in breast 
ap pear ance since radiotherapy 0·79, 0·62–1·02; and 
change in skin appearance since radiotherapy 0·76, 
0·56–1·03).
Pain in the arm and shoulder aﬀ ected up to a third of 
patients over 5 years across regimens, and the 5-year rate 
of moderate or marked shoulder stiﬀ ness was about 20% 
(ﬁ gure 2). The highest symptom subscale scores were 
present at baseline after which time they fell signiﬁ cantly 
(p<0·0001; table 2). Baseline arm and shoulder symptoms 
were associated with axillary surgery (p=0·0129 for arm 
or shoulder pain; p=0·0319 for arm or hand swelling) 
and breast-conserving surgery (p=0·0163 for arm or 
shoulder pain). Within-patient analysis of individual 
items at every timepoint showed that many arm or 
shoulder eﬀ ects persisted from baseline (of 705 patients 
with moderate or marked arm or shoulder pain during 
follow-up, 282 [40%] had symptoms at baseline). 
Arm and shoulder symptom subscale scores did not 
diﬀ er signiﬁ cantly between regimens (p=0·2071 for trial 
A and p=0·3101 for trial B; table 2). In trial A there was 
some evidence of fewer arm and shoulder adverse eﬀ ects 
for the 41·6 Gy and 39 Gy regimens compared with 50 Gy, 
although these were not statistically signiﬁ cant. There 
were no consistent diﬀ erences between the regimens in 
trial B (ﬁ gure 2). 
With respect to body image, 851 of 2117 (40%) women 
with relevant data reported moderate or marked concerns 
on at least one body-image item over 5 years of follow-up. 
Type of primary surgery Radiotherapy boost*
Breast-conserving 
surgery (n=848)
Mastectomy 
(n=232)
Boost (n=611) No boost (n=235)
Change in skin appearance since radiotherapy
50 Gy 1 1 1 1
41·6 Gy 0·92 (0·68–1·25) 0·53 (0·28–0·99) 1·00 (0·71–1·41) 0·72 (0·38–1·35)
39 Gy 0·63 (0·45–0·88) 0·64 (0·34–1·17) 0·58 (0·39–0·86) 0·77 (0·41–1·46)
Skin problems on or in area of aﬀ ected breast†
50 Gy 1 1 1 1
41·6 Gy 1·02 (0·70–1·50) 0·90 (0·39–2·10) 1·16 (0·73–1·84) 0·75 (0·38–1·47)
39 Gy 0·87 (0·58–1·30) 1·07 (0·48–2·38) 0·85 (0·51–1·41) 0·87 (0·45–1·69)
Pain in area of aﬀ ected breast†
50 Gy 1 1 1 1
41·6 Gy 1·29 (0·92–1·82) 0·82 (0·42–1·61) 1·16 (0·78–1·73) 1·77 (0·90–3·48)
39 Gy 1·01 (0·70–1·45) 0·87 (0·45–1·69) 0·84 (0·55–1·28) 1·66 (0·81–3·37)
Oversensitivity in area of aﬀ ected breast†
50 Gy 1 1 1 1
41·6 Gy 1·14 (0·81–1·58) 0·87 (0·42–1·81) 1·00 (0·68–1·48) 1·56 (0·84–2·92)
39 Gy 0·79 (0·55–1·12) 0·81 (0·39–1·68) 0·70 (0·46–1·07) 1·06 (0·55–2·05)
Swelling in area of aﬀ ected breast†
50 Gy 1 1 1 1
41·6 Gy 0·87 (0·58–1·32) 0·40 (0·11–1·51) 0·83 (0·51–1·34) 1·05 (0·46–2·38)
39 Gy 0·68 (0·44–1·05) 0·98 (0·36–2·61) 0·60 (0·36–1·01) 0·96 (0·41–2·21)
Arm or shoulder pain†
50 Gy 1 1 1 1
41·6 Gy 1·05 (0·79–1·39) 0·83 (0·47–1·47) 0·92 (0·65–1·29) 1·62 (0·93–2·84)
39 Gy 1·11 (0·83–1·48) 0·97 (0·56–1·69) 0·95 (0·68–1·33) 1·81 (1·01–3·24)
Shoulder stiﬀ ness†
50 Gy 1 1 1 1
41·6 Gy 0·94 (0·65–1·37) 0·74 (0·37–1·46) 0·89 (0·58–1·38) 1·18 (0·55–2·49)
39 Gy 0·98 (0·67–1·41) 0·45 (0·20–0·99) 0·80 (0·51–1·24) 1·68 (0·81–3·44)
Diﬃ  culty in raising or moving arm sideways†
50 Gy 1 1 1 1
41·6 Gy 1·16 (0·76–1·77) 0·61 (0·30–1·24) 1·12 (0·68–1·85) 1·29 (0·58–2·86)
39 Gy 1·15 (0·75–1·76) 0·61 (0·31–1·23) 1·09 (0·66–1·81) 1·32 (0·61–2·89)
Arm or hand swelling†
50 Gy 1 1 1 1
41·6 Gy 0·77 (0·49–1·21) 1·09 (0·50–2·35) 0·56 (0·32–0·98) 1·45 (0·38–2·18)
39 Gy 0·92 (0·60–1·42) 0·88 (0·40–1·95) 0·88 (0·53–1·44) 0·89 (0·36–2·18)
Data are crude hazard ratio (95% CI). *Breast-conserving patients only; boost unknown for two women. †Results 
adjusted for baseline scores.
Table 3: Survival analyses of moderate or marked grade normal tissue eﬀ ects from patients’ 
self-assessments, according to fractionation schedule, type of primary surgery, and boost in START trial A
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The most typically reported moderate or marked concerns 
were feeling physically less attractive (496/2111 [23%]) 
and dissatisfaction with body (483/2112 [23%]). Body 
image scale summary scores were similar in all regimens 
over time (p=0·9990 for trial A and p=0·3405 for trial B; 
table 2). Analysis of individual item scores showed no 
signiﬁ cant diﬀ erences between regimens. An improve-
ment in body image scale scores was noted for all 
regimens over time compared with baseline (p<0·0001 
in each trial; table 2). 
In subgroup analyses, the relative eﬀ ects of the 
randomised radiotherapy schedules on patient-reported 
symptoms did not vary signiﬁ cantly according to type of 
primary surgery (breast-conserving surgery or mast-
ectomy) or whether or not a radiotherapy boost to the 
tumour bed was given (tables 3–5). Tests for interaction 
were not signiﬁ cant overall, and hazard ratios were 
similar in subgroups. The low numbers of patients and 
events in some subgroups limited the statistical power of 
these analyses. 
Discussion
In our study, detailed self-assessments by patients in the 
START trials of normal tissue responses to breast 
radiotherapy over 5 years provided independent evidence 
that use of a lower overall radiotherapy dose in fewer larger 
fractions does not result in an increase in adverse eﬀ ects or 
worse body image for most women, compared with the 
international standard regimen of 50 Gy in 25 fractions. 
Nevertheless, the experience by patients of breast and arm 
symptoms over 5 years represented chronic morbidity 
across all regimens. Breast pain has been implicated as a 
risk factor for poor long-term quality of life18–20 and should 
be monitored by clinical teams, whereas functional 
symptoms such as shoulder stiﬀ ness could warrant early 
clinical attention. Breast and arm pain and oedema might 
have stronger associations than cosmesis with long-term 
quality of life21 and, therefore, these are important outcomes 
to assess in clinical trials. 
Little investigation has been done of self-reported breast, 
arm, and shoulder symptoms and functional outcomes 
after radiotherapy,21,22 and thus our results make a 
potentially important contribution to the discussion of the 
eﬀ ects of breast radiotherapy for informed consent. The 
ﬁ ndings also highlight the eﬀ ect of previous surgery,23,24 
which should be taken into account when interpreting 
radiotherapy eﬀ ects. The START quality-of-life study was 
designed to capture late eﬀ ects of breast radiotherapy, 
because of concerns about hypofractionated regimens. 
Patients’ reports of transient and short-term eﬀ ects of 
radiotherapy have been reported, with limited eﬀ ect on 
overall quality of life.3,22,25,26 In future trials, well-deﬁ ned, 
frequent, objective, and subjective assessments of relevant 
symptoms are desirable,27,28 to establish the duration and 
functional outcomes of acute eﬀ ects with more precision. 
We have reported adverse eﬀ ects up to 5 years after 
radiotherapy, but we acknowledge that follow-up beyond 
5 years is needed to assess further the pattern and severity 
of normal tissue eﬀ ects, since they cannot be assumed to 
decrease over time, and some eﬀ ects arise much later on. 
Follow-up in the START trials is ongoing, to assess the 
long-term eﬀ ects of the fractionation schedules, although 
ﬁ ndings of the pilot study showed (with median follow-up 
of 10 years) that relative diﬀ erences remained unchanged 
over time.11 Interest in the late eﬀ ects of speciﬁ c treatments 
for breast-cancer survivors is growing, making clinical 
trials a suitable vehicle for gathering these data. The 
potential for continuing or late adverse eﬀ ects adds to the 
importance of ensuring adequate clinical monitoring to 
oﬀ er women appropriate advice and support. 
Breast changes that showed variation between 
radiotherapy regimens did not translate directly into 
diﬀ erences in ratings of general body image concerns, 
suggesting that women did not experience breast changes 
in a way that aﬀ ected their overall body image. This 
ﬁ nding contrasts with the important eﬀ ect on body image 
reported by these women before starting radiotherapy, 
when worse body image was associated with younger 
Type of primary surgery Radiotherapy boost*
Breast-conserving 
surgery (n=911)
Mastectomy (n=126) Boost (n=470) No boost (n=437)
Change in skin appearance since radiotherapy
50 Gy 1 1 1 1
40 Gy 0·80 (0·63–1·03) 0·48 (0·20–1·16) 0·72 (0·52–1·01) 0·88 (0·61–1·27)
Skin problems on or in area of aﬀ ected breast†
50 Gy 1 1 1 1
40 Gy 0·86 (0·65–1·15) 2·26 (0·43–11·80) 0·76 (0·51–1·14) 0·97 (0·64–1·46)
Pain in area of aﬀ ected breast†
50 Gy 1 1 1 1
40 Gy 0·97 (0·74–1·26) 0·63 (0·22–1·79) 1·05 (0·72–1·53) 0·88 (0·59–1·30)
Oversensitivity in area of aﬀ ected breast†
50 Gy 1 1 1 1
40 Gy 1·18 (0·91–1·53) 0·55 (0·19–1·54) 1·33 (0·92–1·90) 1·05 (0·72–1·53)
Swelling in area of aﬀ ected breast†
50 Gy 1 1 1 1
40 Gy 0·89 (0·62–1·29) 4·18 (0·61–28·37) 0·94 (0·57–1·53) 0·80 (0·45–1·42)
Arm or shoulder pain†
50 Gy 1 1 1 1
40 Gy 1·03 (0·83–1·29) 0·92 (0·47–1·80) 1·01 (0·74–1·36) 1·04 (0·75–1·44)
Shoulder stiﬀ ness†
50 Gy 1 1 1 1
40 Gy 0·94 (0·70–1·25) 1·10 (0·47–2·58) 0·87 (0·58–1·31) 1·01 (0·66–1·54)
Diﬃ  culty in raising or moving arm sideways†
50 Gy 1 1 1 1
40 Gy 0·99 (0·73–1·35) 0·79 (0·35–1·77) 0·90 (0·60–1·37) 1·03 (0·65–1·64)
Arm or hand swelling†
50 Gy 1 1 1 1
40 Gy 1·12 (0·78–1·60) 0·65 (0·20–2·17) 0·65 (0·40–1·04) 2·29 (1·29–4·07)
Data are crude hazard ratio (95% CI). *Breast-conserving patients only; boost unknown for four women. †Results 
adjusted for baseline scores.
Table 4: Survival analyses of moderate or marked grade normal tissue eﬀ ects from patients’ self-
assessments according to fractionation schedule, type of primary surgery, and boost in START trial B
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age, having mastectomy, and chemotherapy.13 The 
absence of variation in scores for body image between 
regimens might also indicate that the body image scale is 
designed to assess a range of concerns about overall 
attractiveness and appearance rather than speciﬁ c aspects 
of breast appearance. Use of a radiotherapy boost and 
type of primary surgery have an adverse eﬀ ect on 
cosmesis and patient-reported symptoms,5,8,29 but they 
did not aﬀ ect the comparison of the randomised 
schedules in the START trials. 
In two other randomised controlled trials, researchers 
have compared the long-term eﬀ ect of hypofractionated 
radiotherapy regimens at 5 years, but patient-reported 
normal tissue damage and cosmesis were not recorded.11,30 
The sensitivity of radiation dose to observer-rated breast 
symptoms and appearance was conﬁ rmed in the pilot 
study to the START trials,11 and adverse changes in breast 
appearance from photographic assessments were signiﬁ -
cantly lower in the 39 Gy in 13 fractions regimen compared 
with the 50 Gy in 25 fractions control, with highest rates in 
patients who received 42·9 Gy in 13 fractions. By contrast, 
in a Canadian randomised trial comparing 42·5 Gy in 16 
fractions against 50 Gy in 25 fractions, observer-rated 
cosmesis did not diﬀ er between schedules.30 
The START trials comprise a well-deﬁ ned cohort of 
patients, which is representative of women with early 
breast cancer in the UK. A strength of the quality-of-life 
assessments is the wide age and geographic range of 
participants and high levels of adherence to questionnaire 
completion over time. Individuals in the quality-of-life 
study were recruited from all parts of the UK, although 
London and the south of England were over-represented 
by comparison with annual distribution of new breast 
cancer cases for these areas (46% vs 35%, respectively).31 
Data for ethnic origin were not obtained in the START 
trials, so a statement about generalisability of our ﬁ ndings 
in that respect is not possible. 
To our knowledge, our study is the ﬁ rst in which self-
reported breast symptoms have identiﬁ ed diﬀ erences 
over 5 years between alternative radiotherapy regimens in 
early breast cancer. Our ﬁ ndings accord with observer-rated 
photographic changes reported separately in the START 
trials,1,2 which indicated that the diﬀ erence between the 
two test dose levels in trial A in 2·0 Gy-fraction equivalents 
can be estimated to be 10%. Sensitivity of patients’ self-
ratings is highlighted by discrimination of this modest 
diﬀ erence in dose intensity. The low rate of lymphatic 
radiotherapy given in the trials reduced the ability to 
detect diﬀ erences in arm or shoulder symptoms between 
regimens. In our study, change in skin appearance was 
the outcome over 5 years that best discriminated between 
radiotherapy schedules, but other post-radiotherapy 
eﬀ ects (eg, breast shrinkage and hardness) and breast 
symptoms showed comparable patterns. 
Patients’ perceptions of adverse eﬀ ects are very 
important. We believe patient-reported outcomes should 
be used routinely in randomised trials of radiotherapy, 
where both the symptomatic impact of treatment and the 
extent of disruption to women’s lives relating to length of 
treatment can aﬀ ect quality of life.
In conclusion, considerable morbidity still arises due 
to eﬀ ects on normal tissues of treatments for early breast 
cancer, and patients’ self-assessments are important to 
ascertain the extent and duration of these eﬀ ects. 
However, these ratings by patients in the START trials 
strengthen evidence in favour of hypofractionated 
regimens, with a potential for fewer adverse eﬀ ects on 
the normal breast tissues. These ﬁ ndings have important 
implications for radiotherapy practice with quality-of-life 
beneﬁ ts to patients. 
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Type of primary surgery Radiotherapy boost†
Breast-conserving 
surgery (n=704 [A]; 
n=775 [B])
Mastectomy 
(n=160 [A]; n=82 [B])
Boost (n=512 [A]; 
n=400 [B])
No boost 
(n=349 [A]; 
n=455 [B])
BR23 breast symptoms subscale (0–100)
Trial A
50 Gy 8·3 (0–25·0) 8·3 (0–20·8) 9·7 (0–25·0) 8·3 (0–16·7) 
41·6 Gy 8·3 (0–16·7) 8·3 (0–25·0) 8·3 (0–16·7) 8·3 (0–16·7)
39 Gy 8·3 (0–16·7) 8·3 (0–22·9) 8·3 (0–16·7) 8·3 (0–25·0)
Trial B
50 Gy 8·3 (0–16·7) 8·3 (0–16·7) 8·3 (0–16·7) 8·3 (0–16·7) 
40 Gy 8·3 (0–16·7) 8·3 (0–16·7) 8·3 (0–16·7) 8·3 (0–16·7)
BR23 arm or shoulder symptoms subscale (0–100)
Trial A
50 Gy 11·1 (0–22·2) 11·1 (5·6–33·3) 11·1 (0–22·2) 11·1 (0–33·3) 
41·6 Gy 11·1 (0–22·2) 11·1 (0–33·3) 11·1 (0–22·2) 11·1 (0–22·2)
39 Gy 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
Trial B
50 Gy 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 
40 Gy 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2) 11·1 (0–22·2)
Body image scale (0–30)
Trial A
50 Gy 1·0 (0–5·0) 8·0 (2·2–15·5) 2·0 (0–6·0) 2·0 (0–8·0) 
41·6 Gy 2·0 (0–7·0) 3·0 (0–8·0) 2·0 (0–7·0) 1·5 (0–7·0)
39 Gy 1·0 (0–5·0) 6·0 (1·0–11·0) 1·0 (0–4·0) 4·0 (0–9·0)
Trial B
50 Gy 1·0 (0–5·0) 4·0 (1·0–9·5) 2·0 (0–5·5) 1·0 (0–6·0) 
40 Gy 1·0 (0–5·0) 4·0 (0–7·0) 1·0 (0–6·0) 2·0 (0–5·0)
Data are median (IQR). Higher scores indicate more symptoms or concerns. *Subgroup analyses undertaken with all 
follow-up data in generalised estimating equation models, but only 5-year data are shown for simplicity of 
presentation. †Breast-conserving surgery patients only.
Table 5: Breast, arm, or shoulder symptoms and body image scale scores at 5 years* according to 
radiotherapy regimen, type of primary surgery, and boost
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